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Abstract 
Cytoprotection by activated protein C (aPC) after ischemia-reperfusion injury (IRI) is associated with 
apoptosis inhibition. However, IRI is hallmarked by inflammation, and hence, cell-death forms disjunct 
from immunologically silent apoptosis are, in theory, more likely to be relevant. Because pyroptosis (ie, 
cell death resulting from inflammasome activation) is typically observed in IRI, we speculated that aPC 
ameliorates IRI by inhibiting inflammasome activation. Here we analyzed the impact of aPC on 
inflammasome activity in myocardial and renal IRIs. aPC treatment before or after myocardial IRI 
reduced infarct size and Nlrp3 inflammasome activation in mice. Kinetic in vivo analyses revealed that 
Nlrp3 inflammasome activation preceded myocardial injury and apoptosis, corroborating a pathogenic 
role of the Nlrp3 inflammasome. The constitutively active Nlrp3A350V mutation abolished the protective 
effect of aPC, demonstrating that Nlrp3 suppression is required for aPC-mediated protection from IRI. 
In vitro aPC inhibited inflammasome activation in macrophages, cardiomyocytes, and cardiac 
fibroblasts via proteinase-activated receptor 1 (PAR-1) and mammalian target of rapamycin complex 1 
(mTORC1) signaling. Accordingly, inhibiting PAR-1 signaling, but not the anticoagulant properties of 
aPC, abolished the ability of aPC to restrict Nlrp3 inflammasome activity and tissue damage in 
myocardial IRI. Targeting biased PAR-1 signaling via parmodulin-2 restricted mTORC1 and Nlrp3 
inflammasome activation and limited myocardial IRI as efficiently as aPC. The relevance of aPC-
mediated Nlrp3 inflammasome suppression after IRI was corroborated in renal IRI, where the tissue 
protective effect of aPC was likewise dependent on Nlrp3 inflammasome suppression. These studies 
reveal that aPC protects from IRI by restricting mTORC1-dependent inflammasome activation and that 
mimicking biased aPC PAR-1 signaling using parmodulins may be a feasible therapeutic approach to 
combat IRI. 
Introduction 
Myocardial infarction (MI) is a major cause of death worldwide. Rapid diagnosis and reperfusion 
improve survival after MI. However, cardiac ischemia-reperfusion injury (IRI) triggers pronounced 
tissue-disruptive and sterile proinflammatory responses, which compromise outcome.1-3 Induction of 
interleukin-1β (IL-1β) and IL-18, which are controlled by the Nlrp3 inflammasome, contribute to the 
tissue-disruptive and proinflammatory responses.4,5 Importantly, Nlrp3 inflammasome inhibition 
reduces infarct size, attenuates adverse cardiac remodeling, and preserves cardiac function in animal 
models of MI.6-8 
The inflammasome is a signaling platform detecting pathogenic microorganisms and sterile stressors.9 
Sensor molecules, which typically contain a NOD-like receptor (Nlr; eg, Nlrp1, Nlrp3, or Nlrc4), detect 
appropriate stimuli and form a complex with ASC, an adaptor protein encoded by PYCARD. ASC 
contains a pyrin domain and a caspase activation and recruitment domain (CARD). Via its pyrin domain, 
ASC interacts with the sensor molecule, and the CARD domain interacts with caspase-1 and initiates 
caspase-1 self-cleavage. Activated caspase-1 proteolytically activates pro–IL-1β and pro–IL-18, inducing 
their release via a nonclassical secretion pathway. The activation of the Nlrp3 inflammasome 
comprises 2 steps: during the priming step, Nlrp3 expression is induced, and during the activation step, 
the oligomeric inflammasome complex assembles, inducing maturation of IL-1β and IL-18.9 
IL-1 receptor antagonist is an endogenous Nlrp3 inflammasome inhibitor during IRI.10,11 However, its 
induction after myocardial IRI is insufficient to provide full protection, which may reflect higher affinity 
of IL-1 for the receptor or excess availability of IL-1 receptor.12 Thus, deciphering independent 
pathways enabling Nlrp3 inflammasome restriction is required to identify suitable therapeutic 
strategies. Like inflammation, mammalian target of rapamycin (mTOR) signaling and coagulation 
proteases modulate myocardial IRI, but whether these systems are mechanistically linked remains 
unknown.13,14 
An important endogenous inhibitor of inflammation is the coagulation protease–activated protein C 
(aPC). Given its strong anti-inflammatory properties, human recombinant aPC received approval for 
sepsis treatment, but it was eventually withdrawn from the market, partially because of failure to 
replicate efficacy.15,16 Variants of aPC with reduced anticoagulant activity are currently undergoing 
clinical evaluation for stroke15 (registered at www.clinicaltrials.gov as #NCT02222714). In regard to 
myocardial IRI, several studies have demonstrated cardioprotection by aPC, which has been linked with 
apoptosis inhibition.17-22 However, apoptosis is an immunogenically silent cell-death form and is less 
likely to promote myocardial IRI than other cell-death forms associated with inflammation, such as 
pyroptosis.23 Considering the close association of myocardial IRI, as well as other forms of IRI, with a 
strong sterile inflammatory response and the anti-inflammatory effect of aPC, we hypothesized that 
aPC restricts inflammasome activation in IRI. 
Methods 
See the supplemental Data, available on the Blood Web site, for additional information. 
Mice 
Proteinase-activated receptor 2−/− (PAR-2−/−), (PAR-3−/−), Nlrp3A350V LoxP/LoxP, and RosaERTCre mice were 
obtained from Jackson Laboratory (Bar Harbor, ME). PAR-1−/− and TSC1LoxP/LoxP mice were kindly 
provided by E.C. (Paris, France) and T.B.H. (Hamburg, Germany), respectively. Wild-type mice 
(C57BL/6) were obtained from Janvier Labs (Le Genest-Saint-Isle, France). In the current study, we used 
littermates that had been backcrossed for at least 10 generations on a C57BL/6J background. Only age-
matched mice were used throughout the study. All animal experiments were conducted following 
standards and procedures approved by the local animal care and use committee 
(Landesverwaltungsamt, Halle, Germany). 
In vivo intervention studies 
For the myocardial IRI model (left anterior descending artery ligation for 90 minutes followed by 24 
hours of reperfusion), mice were injected with phosphate-buffered saline (PBS; control; equal volume 
intraperitoneally [IP]), aPC (1 mg/kg IP),24 aPC-HAPC1573 complex (aPC was preincubated before 
injection with HAPC1573 antibody at a 1:1 molar ratio for 10 minutes under gentle agitation to block its 
anticoagulant activity),24⇓⇓-27 an aPC variant lacking specifically anticoagulant function (3K3A-aPC; 1 
mg/kg IP),28,29 the inhibitory PAR-1 pepducin (P1pal-12S; 2.5 mg/kg subcutaneously) followed by aPC (1 
mg/kg IP),26,30,31 or parmodulin-2 (5 mg/kg IV)32 30 minutes before myocardial IRI. A subset of mice was 
treated with PBS (control; equal volume IP) or aPC (1 mg/kg IP) 30 minutes after starting reperfusion. 
In renal IRI experiments (bilateral renal pedicle occlusion for 30 minutes followed by 24 hours of 
reperfusion),25 mice were injected with PBS (control; 1 mg/kg IP) or aPC (1 mg/kg IP) 30 minutes before 
IRI. P1pal-12S and parmodulin-2 have been previously described.30-33 Infarct size was determined as 
described in the supplemental Methods. 
Caspase-1 activity assay 
Caspase-1 activity was determined on frozen heart sections using the FLICA Casp-1 assay 
(Immunochemistry Technologies LCC) as described.34 
Cell culture 
Primary mouse bone marrow–derived macrophages (BMDMs), neonatal cardiomyocytes, and neonatal 
cardiac fibroblasts were isolated and cultured as described elsewhere.35,36 
Statistical analysis 
The data are summarized as the mean ± standard error of the mean (SEM). Statistical analyses were 
performed with the Student t test, the Mann-Whitney U test, or analysis of variance, as appropriate. 
Post hoc comparisons of analysis of variance were corrected with the method of Tukey. The 
Kolmogorov-Smirnov test or the D’Agostino-Pearson normality test was used to determine whether 
the data were consistent with a Gaussian distribution. Prism 5 software (www.graphpad.com) was 
used for statistical analyses. Statistical significance was accepted at P values <.05. 
Results 
aPC restricts inflammasome activation after myocardial IRI 
To determine whether aPC restricts inflammasome activation in myocardial IRI, we treated mice with 
aPC (1 mg/kg IP) or PBS (control). After 30 minutes, we induced myocardial ischemia for 90 minutes 
and analyzed mice after 24 hours of reperfusion (Figure 1A). Congruent with previous reports, aPC 
markedly reduced infarct size (Figure 1B-C).17-22 Reduction of infarct size by aPC was associated with 
reduced inflammasome activation within the heart. Cardiac expression of Nlrp3 and cl-Casp1 and cl–IL-
1β were increased after myocardial IRI but reduced after aPC pretreatment (Figure 1D-E). 
Concurrently, in situ caspase-1 activity after myocardial IRI was reduced by aPC (Figure 1F-G). These 
changes were reflected by plasma cytokine levels. Thus, increased plasma IL-1β and IL-18 levels after 
myocardial IRI were attenuated by aPC (Figure 1H-I). Additionally, treatment with aPC after myocardial 
IRI reduced myocardial infarct size and markers of inflammasome activation within the heart and 
plasma as efficiently as aPC pretreatment (supplemental Figure 1A-G). Thus, aPC efficiently restricts 
inflammasome activation after myocardial IRI. 
Figure 1.  
 
aPC ameliorates inflammasome activation after myocardial IRI. (A) Experimental design. (B-C) aPC treatment reduces 
infarct size. Representative heart sections showing infarcted area detected by triphenyl tetrazolium chloride staining (area 
encircled by dashed line; size bar, 20 µm) (B) and dot plot summarizing data (C). (D-I) aPC pretreatment significantly 
reduces cardiac Nlrp3 expression and cleavage of caspase-1 (cl-Casp1) and IL-1β (cl–IL-1β). Representative immunoblots 
(glyceraldehyde-3-phosphate dehydrogenase [GAPDH]: loading control [cont]) (D) and bar graph summarizing data (E). 
Arrowheads indicate inactive (white) and active (black) forms of caspase-1 or IL-1β (D). The active form was quantified (E). 
aPC treatment reduces caspase-1 activity within infarcted area. Representative images of frozen sections incubated with 
FLICA-Casp1 probes (size bar, 20 µm) (F) and dot plot summarizing data (G). aPC reduces plasma IL-1β (H) and IL-18 levels (I) 
after myocardial IRI; dot plots summarizing data. Sham-operated mice (sham) or mice with myocardial IRI without (cont; 
PBS) or with aPC pretreatment (aPC). Data shown represent mean ± SEM of at least 6 mice per group. *P < .05, **P < .01; 
analysis of variance (C,E,H,I) or Mann-Whitney U test (G). 
 
 
Inflammasome activation precedes apoptosis after myocardial IRI 
Amelioration of myocardial IRI by aPC has been associated with reduced apoptosis, an immunologically 
silent form of cell death. However, myocardial IRI is strongly associated with inflammation,37 and 
hence, we speculated that inflammasome activation might be the leading pathomechanism. To gain 
insights into the temporal pattern of inflammasome and apoptosis activation after myocardial IRI, we 
conducted kinetic studies. Hearts isolated at various time points after reperfusion (1-24 hours) were 
compared with hearts of sham-operated mice. An infarcted area was detected as early as 3 hours after 
reperfusion (Figure 2A-B). Inflammasome activation within the heart preceded the detectable infarcted 
area (1-hour time point; cl-Casp1 and cl–IL-1β; Figure 2C-D), whereas markers of apoptosis activation 
increased at later time points (12-hour time point; cl-Casp3, cl-Casp7, BAX; Figure 2C-D). These data 
establish that myocardial inflammasome activation occurs early in IRI and precedes the detection of an 
infarcted area and, importantly, apoptosis activation. 
Figure 2.  
 
Pivotal function of Nlrp3 inflammasome in myocardial IRI. (A-D) Kinetic analyses of infarct size and markers of 
inflammasome and apoptosis activation in hearts isolated at various time points after IRI (1-24 hours) compared with sham-
operated mice. Representative images of triphenyl tetrazolium chloride (TTC) staining (infarct area encircled by dashed line; 
size bar, 20 µm) (A), dot plot summarizing data of infarct size (individual data points and mean ± SEM) (B), and 
representative immunoblots of inflammasome (cl-Casp1, cl–IL-1β) or apoptosis activation (cl-Casp3, cl-Casp7, BAX 
expression) markers, with glyceraldehyde-3-phosphate dehydrogenase [GAPDH] as loading control (C). (D) Line graph 
summarizing immunoblot data (mean ± SEM). (E) Experimental design. (F-L) Constitutively active Nlrp3A350V abolishes the 
protective effect of aPC in myocardial IRI. (F) Induction of Nlrp3A350V expression after tamoxifen injection into Nlrp3V-ER mice 
compared with PBS-treated mice; representative immunoblots, with GAPDH as loading control. (G-H) aPC treatment fails to 
protect against myocardial IRI in Nlrp3V-ER mice. Representative heart sections showing infarcted area detected by TTC 
staining (area encircled by dashed line; size bar, 20 µm) (G) and dot plot summarizing data (H). (I-L) aPC fails to reduce Nlrp3 
expression, cl-Casp1 or cl–IL-1β, or plasma IL-1β and IL-18 levels in Nlrp3V-ER mice after myocardial IRI. Representative 
immunoblots (I) and bar graphs (J) summarizing results, with GAPDH as loading control; arrowheads indicate inactive 
(white) and active (black) forms of caspase-1 or IL-1β (I). (J) The active form was quantified. (K-L) Dot plots of plasma IL-1β 
and IL-18 levels. Sham-operated mice (sham) or mice with myocardial IRI without (cont; PBS) or with aPC pretreatment 
(aPC). Data shown represent mean ± SEM of at least 6 mice per group. *P < .05, **P < .01; Student t test (B,D) or analysis of 
variance (H,J-L). 
Constitutively active Nlrp3 abolishes the protective effect of aPC in 
myocardial IRI 
The kinetics of inflammasome and apoptosis activation after myocardial IRI suggest that inflammasome 
activation is the culprit and hence that inflammasome suppression is the primary mechanism 
underlying the cytoprotective effect of aPC after myocardial IRI. To ascertain whether inflammasome 
restriction is required for the protective effect of aPC in myocardial IRI, we crossed mice containing an 
inducible Nlrp3 gain-of-function mutation (Nlrp3A350V LoxP/LoxP [LoxP-Cre recombinase–dependent 
expression of the constitutively active Nlrp3A350V mutation]) with mice ubiquitously expressing 
inducible Cre recombinase under the control of the estrogen receptor T2 (Rosa Cre-ERT2), yielding 
Nlrp3A350V LoxP/LoxPx Rosa Cre-ERT2 mice (hereafter referred to as Nlrp3V-ER mice). Expression of the 
Nlrp3A350V mutation does not cause heart injury by itself and requires a second stimulus for 
inflammasome activation.38 Mice were treated for 5 days with tamoxifen (5 mg/kg IP) or PBS (control), 
which increased Nlrp3 expression in tamoxifen-treated mice (Figure 2E-F). Mice were injected with aPC 
or PBS (control) 24 hours after the last tamoxifen injection. After another 30 minutes, myocardial 
ischemia was induced for 90 minutes, and analyses were conducted 24 hours after reperfusion (Figure 
2E). In tamoxifen-treated but sham-operated mice, no myocardial infarction was detected (Figure 2G-
H), and indices of inflammasome activation remained normal (Figure 2I-L), corroborating that 
expression of Nlrp3A350V mutation is not sufficient to cause myocardial inflammasome activation. After 
myocardial IRI, an infarcted area was readily detectable in Nlrp3V-ER mice (Figure 2G-H). Importantly, 
aPC treatment failed to reduce the infarct size in Nlrp3V-ER mice (Figure 2G-H). Concurrently, aPC failed 
to reduce protein levels of Nlrp3, cl-Casp1 or cl–IL-1β (Figure 2I-J), or plasma IL-1β and IL-18 levels 
(Figure 2K-L) in Nlrp3V-ER mice after myocardial IRI. These data establish that in mice with a genetically 
superimposed bias for inflammasome activation, the protective effect of aPC in myocardial IRI is lost. 
aPC prevents inflammasome activation in cardiac resident cells and 
macrophages in vitro 
The role of the inflammasome in innate immune cells like macrophages is firmly established, but recent 
data have demonstrated functional inflammasome in tissue-resident cells, including cardiomyocytes.6,8 
To identify in which cell types aPC prevents inflammasome activation in myocardial IRI, we isolated 
primary BMDMs, primary neonatal cardiomyocytes, and primary neonatal cardiac fibroblasts. Cells 
were primed with lipopolysaccharide (LPS; 500 ng/mL), and after 3 hours, cells were exposed to aPC 
(20 nM) or PBS (control). After 1 hour, cells were exposed to adenosine triphosphate (ATP) or PBS 
(control) for 3 hours to activate the Nlrp3 inflammasome.39,40 The LPS/ATP-mediated induction of 
Nlrp3 expression and cl-Casp1 and cl–IL-1β were prevented by aPC in all 3 cell types (Figure 3A-F). 
Thus, aPC dampens inflammasome activation not only in innate immune cells but also in resident 
cardiac cells. Although ATP is considered to induce inflammasome activation during myocardial IRI,38 
we ascertained the efficacy of aPC in the context of hypoxia reoxygenation (H/R) injury in 
cardiomyocytes. Exposure of primary neonatal cardiomyocytes to hypoxia (6 hours) followed by 
reoxygenation (12 hours) without prior LPS stimulation was sufficient for inflammasome activation, 
increased Nlrp3 expression, and cl-Casp1 and cl–IL-1β (Figure 3G-H). H/R-induced inflammasome 
activation in primary cardiomyocytes was efficiently prevented by aPC (Figure 3G-H). Taken together, 
these findings show aPC prevents inflammasome activation both in innate immune cells (macrophages) 
and in resident cardiac cells (cardiomyocytes, cardiac fibroblasts). 
Figure 3.  
 
aPC prevents inflammasome activation in cardiac resident cells and macrophages in vitro. (A-F) In mouse BMDMs (A-B), 
mouse neonatal cardiomyocytes (C-D), and mouse neonatal cardiac fibroblasts (E-F), inflammasome activation was induced 
by priming with LPS (500 ng/mL, 3 hours) followed by ATP (10 µM, 3 hours; control [cont]: PBS). Concomitant treatment 
with aPC (20 nM; added once 30 minutes before ATP stimulation) markedly reduced the LPS/ATP-mediated induction of 
Nlrp3 and cl-Casp1 and cl–IL-1β; representative immunoblots (A,C,E) and corresponding bar graphs summarizing results 
(B,D,F). Arrowheads indicate inactive (white) and active (black) forms of caspase-1 or IL-1β (A,C,E). (B,D,F) The active form 
was quantified. (G-H) Nlrp3 expression and cl-Casp1 and cl–IL-1β are increased in mouse neonatal cardiomyocytes 
subjected to 6 hours of hypoxia (H; 1% oxygen) and serum and glucose deprivation (Hanks balanced salt solution medium), 
followed by 12 hours of reoxygenation (R; 21% oxygen) in complete medium. H/R induces inflammasome activation, which 
is prevented by aPC (20 nM; added once at the time of R); representative immunoblots of whole-cell lysates (G) and bar 
graph summarizing results (H), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control. (G) 
Arrowheads indicate inactive (white) and active (black) forms of caspase-1 or IL-1β, respectively. (H) The active form was 
quantified. Data shown represent mean ± SEM. Data obtained from at least 3 independent experiments, each with at least 
2 technical replicates (A-H); GAPDH as loading control (A,C,E,G). **P < .01; analysis of variance (B,D,F,H). 
aPC restricts inflammasome by suppressing mTORC1 and HK1 
We next investigated the underlying mechanism by which aPC restricts Nlrp3 inflammasome 
activation. Cardioprotection by aPC after IRI has been linked with 5′ adenosine monophosphate–
activated protein kinase (AMPK) activation.21 Furthermore, mTOR complex 1 (mTORC1), which is 
negatively regulated by AMPK, was recently shown to activate Nlrp3 inflammasome in macrophages 
via hexokinase 1 (HK1).40 Hence, we speculated that aPC restricts inflammasome activation by 
restricting mTORC1 signaling in the setting of myocardial IRI. To this end, we determined expression of 
Raptor (regulatory-associated protein of mTOR) and HK1 as well as total and phosphorylated ribosomal 
p70-S6 kinase (p70S6K) in BMDMs, neonatal cardiac fibroblasts, and neonatal cardiomyocytes. 
Expression of Raptor and HK1 and phosphorylation of p70S6K were enhanced in LPS-primed ATP-
stimulated BMDMs and neonatal cardiac fibroblasts (Figure 4A-B; supplemental Figure 2A-B),40 as well 
as in neonatal cardiomyocytes subjected to H/R (Figure 4C; supplemental Figure 2C). Treatment with 
aPC normalized expression of Raptor and HK1 and p70S6K phosphorylation levels in LPS-primed and 
ATP-stimulated cells or in H/R-injured primary cardiomyocytes (Figure 4A-C; supplemental Figure 2A-
C). To corroborate the in vivo relevance of these findings, we analyzed heart tissue of mice with 
myocardial IRI. Treatment with aPC markedly reduced expression of Raptor and HK1 as well as 
phosphorylation of p70S6K in comparison with PBS-treated mice (control; Figure 4D-E). These data 
suggest that aPC restricts inflammasome activation by limiting mTORC1 activation. 
Figure 4.  
 
aPC restricts inflammasome by suppressing mTORC1. (A-C) Expression of Raptor, and HK1 and phosphorylation (phospho) 
of ribosomal p70-S6 kinase (pS6K70) were analyzed in LPS-primed and ATP-challenged BMDMs (A) and mouse neonatal 
cardiac fibroblasts (B) or mouse neonatal cardiomyocytes subjected to hypoxia/reoxygenation (H/R) (C). aPC inhibits 
expression of Raptor and HK1 and p70S6K phosphorylation levels in LPS-primed and ATP-stimulated cells (A-B) or in H/R-
injured primary cardiomyocytes (C). (D-E) Treatment of mice with aPC inhibits mTORC1 signaling; representative 
immunoblots showing cardiac Raptor and HK1 expression as well as total and phosphorylated pS6K70. Representative 
immunoblots (D) and bar graph summarizing results (E). (F-J) BMDMs from TSC1LoxP/LoxP mice were transiently transfected 
with GFP- or Cre-expressing plasmids, resulting in loss of TSC1 expression after 48 hours. Representative immunoblots of 
TSC1, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control (cont) (F). (G-H) In TSC1-deficient 
BMDM cells, aPC treatment fails to reduce Raptor or HK1 expression or phosphorylation of p70S6K (TSC1LoxP/LoxP+Cre+aPC) 
when compared with PBS-treated cells (TSC1LoxP/LoxP+Cre+PBS) Representative immunoblots (G) and bar graph summarizing 
results (H). (I-J) Likewise, aPC fails to reduce Nlrp3 expression or cl-Casp1 or cl–IL-1β in TSC1-deficient BMDMs. 
Representative immunoblots (I) and bar graph summarizing results (J). (I) Arrowheads indicate inactive (white) and active 
(black) forms of caspase-1 or IL-1β. (J) The active form was quantified. Data shown represent mean ± SEM. Data obtained 
from at least 3 independent experiments each with at least 2 technical replicates (A-J); GAPDH as loading control (A-D,F-
G,I). **P < .01; analysis of variance (E,H,J). 
To determine the mechanistic relevance of aPC-dependent mTORC1 regulation for inflammasome 
restriction, we used cells lacking TSC1. TSC1 is a pivotal inhibitor of mTORC1, and its deficiency causes 
constitutive mTORC1 activation.41 BMDMs were isolated from mice with inducible TSC1 deficiency, and 
TSC1 expression was inhibited by transient expression with Cre recombinase ex vivo41 (Figure 4F; 
control cells transiently expressed GFP). In TSC1-deficient BMDMs, aPC failed to inhibit expression of 
Raptor and HK1 and phosphorylation of p70S6K (Figure 4G-H), and importantly, aPC-mediated Nlrp3 
inflammasome restriction was abolished (Figure 4I-J). These results demonstrate that constitutive 
activation of mTORC1 signaling abolishes the inhibitory effect of aPC on inflammasome activation, 
establishing that aPC limits inflammasome activation by restricting mTORC1 activation. 
aPC restricts inflammasome activation via PAR-1 
To gain additional mechanistic insights and identify potential therapeutic targets, we ascertained the 
receptors involved. First, we analyzed expression of PARs and endothelial PC receptor (EPCR) in the 
different cell types employed in our study. Expression of PAR-1, PAR-2, PAR-3, PAR-4, and EPCR was 
readily detectable in these cells (supplemental Figure 3A). To determine the functional relevance of 
these receptors, we isolated BMDMs, neonatal cardiomyocytes, and cardiac fibroblasts from PAR-1−/−, 
PAR-2−/−, or PAR-3−/− mice, and PAR-4 or EPCR function was blocked in wild-type cells using inhibitory 
antibodies.25,26 PAR-1 deficiency efficiently abolished Nlrp3 inflammasome suppression by aPC, 
whereas PAR-2 or PAR-3 deficiency and PAR-4 or EPCR blockage had no effect in any cell type studied 
(Figure 5A-C; supplemental Figure 3B-G). These in vitro results suggest that aPC restricts the 
inflammasome activation via PAR-1 in various cell types relevant for myocardial IRI. 
Figure 5.  
 
aPC restricts inflammasome activation via PAR-1 after myocardial IRI. (A-C) The effect of aPC on inflammasome activation 
was analyzed after receptor inhibition. BMDMs (A), neonatal cardiomyocytes (B), or neonatal cardiac fibroblasts (C) were 
isolated from wild-type (WT), PAR-1−/−, PAR-2−/−, or PAR-3−/− mice. aPC fails to supress LPS/ATP- (A,C) or 
hypoxia/reoxygenation-induced (B) Nlrp3 expression and cl-Casp1 and cl–IL-1β in the absence of PAR-1 in all cell types, 
whereas loss of other receptors had no effect; representative immunoblots, with glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as loading control (A-C). (D) Experimental design. (E-F) Treatment of mice with aPC-HAPC1573 
complex or 3K3A-aPC reduces the infarct size as efficiently as aPC, and blocking PAR-1 signaling (pepducin P1pal-12S) 
abolishes the inhibitory effect of aPC. Representative heart sections showing infarcted area detected by triphenyl 
tetrazolium chloride staining (area encircled by dashed line; size bar, 20 µm) (E) and dot plots summarizing data (F). (G-J) 
Treatment of mice with aPC-HAPC1573 complex or 3K3A-aPC reduces markers of inflammasome activation as efficiently as 
aPC, and blocking PAR-1 signaling (pepducin P1pal-12S) abolishes the inhibitory effect of aPC. (G) Representative 
immunoblots of cardiac Nlrp3 expression and cl-Casp1 and cl–IL-1β, with GAPDH as loading control (cont); arrowheads 
indicate inactive (white) and active (black) forms of caspase-1 or IL-1β. (H) Representative images of active caspase-1 within 
the infarcted tissue (frozen sections incubated with FLICA-Casp1 probes; size bar, 20 µm). Dot plots summarizing plasma IL-
1β (I) and IL-18 (J) levels. Sham-operated (sham) or mice with myocardial IRI without (PBS; cont), with aPC (aPC), with aPC-
HAPC1573 complex (aPC+HAPC1573), with an aPC variant specifically lacking anticoagulant function (3K3A-aPC), or with 
aPC and PAR-1 pepducin P1pal-12S (aPC+P1pal-12S) pretreatment. Data shown represent mean ± SEM. Data obtained from 
at least 3 independent experiments each with at least 2 technical replicates (A-C) or from at least 6 mice per group (D-J). 
**P < .01; analysis of variance (F,I-J). 
To corroborate the in vivo relevance of the in vitro receptor studies, we employed the myocardial IRI 
model. Before myocardial IRI, mice were exposed to PBS (control), aPC alone, the aPC-HAPC1573 
complex (the antibody HAPC1573 specifically blocks the anticoagulant function of aPC),24⇓⇓-27 or an aPC 
variant specifically lacking anticoagulant function (3K3A-aPC),28,29 or they were first treated with an 
inhibitory PAR-1 pepducin (P1pal-12S)26,30,31 followed by aPC treatment. Treatment with 3K3A-aPC or 
preincubation of aPC with the HAPC1573 antibody did not abolish the protective effect of aPC, as 
reflected by reduced infarct size (Figure 5D-F), reduced myocardial Nlrp3 expression and reduced cl-
Casp1 and cl–IL-1β (Figure 5G; supplemental Figure 4A), reduced myocardial caspase-1 activity (FLICA-
Casp1 assay; Figure 5H; supplemental Figure 4B), and reduced plasma IL-1β and IL-18 levels (Figure 5I-
J). However, after inhibition of PAR-1, all these protective effects of aPC were lost (Figure 5D-J), 
verifying a pivotal function of PAR-1 in the cardioprotective effect of aPC in regard to myocardial IRI 
and inflammasome suppression. 
PAR-1–specific parmodulin ameliorates inflammasome activation in 
myocardial IRI 
Considering that aPC predominately requires PAR-1 for inflammasome restriction after myocardial IRI, 
we speculated that targeting PAR-1 would be sufficient to mimic the effect of aPC. However, PAR-1 has 
pleiotropic effects and, depending on the activator and coreceptors involved, can convey via biased 
signaling cell-damaging or cell-protective effects.15,42 Recently, structural biochemistry–created 
compounds, parmodulins, were shown to block only specific aspects of biased PAR signaling.32 We 
used parmodulin-2, which blocks cytodisruptive, but not cytoprotective, PAR-1 signaling32 and 
evaluated its anti-inflammatory and cytoprotective effects in myocardial IRI. Treatment of mice with 
parmodulin-2 (5 mg/kg; Figure 6A) before myocardial IRI was as sufficient as that with aPC, reducing 
the infarct size (Figure 6B-C), cardiac expression of inflammasome regulators (Nlrp3, cl-Casp1, cl-IL1β; 
Figure 6D-E), and plasma IL-1β levels (Figure 6F). Furthermore, parmodulin-2 efficiently reduced 
expression of Raptor and HK1 and phosphorylation of p70S6K (Figure 6G-H). Thus, mimicking biased 
aPC signaling via PAR-1 using parmodulins is sufficient to limit inflammasome activity and convey 
cardioprotection in myocardial IRI. 
  
Figure 6.  
 
Par-1–specific parmodulin ameliorates inflammasome activation in myocardial IRI. (A) Experimental design. (B-C) The 
biased PAR-1 antagonist parmodulin-2 (5 mg/kg) reduces the infarcted area to the same extent as aPC. Representative 
heart sections showing infarcted area detected by TTC staining (infarcted area encircled by dashed line; size bar, 20 µm) (B) 
and dot plot summarizing data (C). (D-H) Treatment of mice with parmodulin-2 reduces markers of inflammasome 
activation and mTORC1 signaling as efficiently as aPC. Representative immunoblots showing cardiac Nlrp3 expression and 
cl-Casp1 and cl–IL-1β (D) and bar graph summarizing results, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
loading control (cont) (E). (D) Arrowheads indicate inactive (white) and active (black) forms of caspase-1 or IL-1β. (E) The 
active form was quantified. Dot plots summarizing plasma IL-1β (F) and representative immunoblots showing Raptor and 
HK1 expression and total and phosphorylated p70S6K (G) and bar graph summarizing results, with GAPDH as loading 
control (H). Sham-operated mice (sham) or mice with myocardial IRI without (cont; PBS) or with aPC (aPC) or parmodulin-2 
(parmodulin) pretreatment. Data shown represent mean ± SEM of at least 6 mice per group (B-H). **P < .01; analysis of 
variance (C,E-F,H). 
aPC protects against renal IRI by limiting Nlrp3 inflammasome activity 
Considering recent data showing that inflammasome activation contributes to IRI in other tissues, 
including the kidney,43,44 we speculated that inflammasome suppression by aPC may have implications 
beyond myocardial IRI. To this end, we induced renal IRI following an established protocol.25 Mice were 
pretreated with aPC (1 mg/kg bodyweight IP) or PBS 30 minutes before renal IRI (bilateral renal pedicle 
occlusion, 30 minutes). After 24 hours, we determined indices of renal failure and inflammasome 
activation (Figure 7A). As expected, BUN, creatinine, tubular injury, and expression of KIM-1 (kidney-
injury-molecule 1) were induced in control mice as compared with sham-operated mice (Figure 7B-C; 
supplemental Figure 5A-C). Likewise, renal expression of Nlrp3 and cl-Casp1 and cl–IL-1β as well as the 
presence of cl-Casp1 within renal medullary tubular cells were markedly reduced by aPC treatment 
(Figure 7D-G). In parallel, aPC treatment decreased plasma cytokines (IL-1β, IL-18; Figure 7H-I). 
Importantly, Nlrp3 expression, which conveys renal injury at least in part independent of the canonical 
inflammasome (caspase-1, IL-1β, IL-18), was not different in aPC-treated and sham-operated mice, 
suggesting that aPC treatment efficiently blocks canonical and noncanonical effects of Nlrp3. 
Congruent with results from myocardial IRI (Figure 2), aPC failed to reduce inflammasome activation or 
protect against renal IRI in Nlrp3V-ER mice (Figure 7J-P; supplemental Figure 6A-C). Thus, as in the heart, 
renal inflammasome restriction by aPC depends on Nlrp3 suppression. 
Figure 7.  
 
aPC restricts Nlrp3 inflammasome activation in renal IRI. (A) Experimental design. aPC treatment reduces plasma BUN (B) 
and creatinine (C) levels in mice with bilateral renal pedicle occlusion (30 minutes) and reperfusion for 24 hours. (D-I) aPC 
reduces renal IRI-induced inflammasome activation. Representative immunoblots of renal Nlrp3 expression and cl-Casp1 
and cl–IL-1β (D) and bar graph summarizing results, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading 
control (cont) (E). (D) Arrowheads indicate inactive (white) and active (black) forms of caspase-1 or IL-1β. (E) The active 
form was quantified. Representative images of active caspase-1 within renal medullary tubular cells (frozen sections 
antibody specific for cl-Casp1; size bar, 20 µm) (F) and dot plot summarizing data (G). Dot plots summarizing plasma IL-1β 
(H) and IL-18 levels (I). (J) Experimental design. (K-P) aPC fails to reduce Nlrp3 expression, cl-Casp1 or cl–IL-1β, or plasma IL-
1β or IL-18 levels in Nlrp3V-ER mice after renal IRI. Plasma BUN (K) and creatinine (L) levels (dot plots); representative 
immunoblots of renal Nlrp3 expression and cl-Casp1 and cl–IL-1β) (M) and bar graph summarizing results (N). Arrowheads 
indicate inactive (white) and active (black) forms of caspase-1 or IL-1β (M); only the active form was quantified (N); GAPDH 
as loading control; dot plots of plasma IL-1β and IL-18 levels (O-P). Sham-operated mice (sham) or mice with renal IRI 
without (cont; PBS) or with aPC pretreatment (aPC) treatment. Data shown represent mean ± SEM of at least 6 different 
mice per group (B-I,K-P). **P < .01; analysis of variance (B-C,E,G-I,K-L,N-P). 
Discussion 
Here we establish that aPC is an endogenous negative regulator of inflammasome activation after IRI, 
uncovering a new anti-inflammatory mechanism of aPC. We used 2 independent models, myocardial 
and renal IRIs, to demonstrate that aPC restricts Nlrp3 expression and activation of caspase-1 and IL-
1β. aPC treatment after onset of IRI efficiently restricts Nlrp3 inflammasome activation and is sufficient 
for cytoprotection, which is congruent with an improved outcome after inflammasome inhibition after 
myocardial IRI.4 In addition, we demonstrate that inflammasome restriction by aPC is independent of 
its anticoagulant properties but depends on signaling via PAR-1. Importantly, a biased agonist of PAR-1 
(parmodulin-2) mimics inflammasome suppression and cytoprotection after myocardial IRI. Thus, we 
propose that biased agonists mimicking aPC signaling may be a new therapeutic approach in IRI. 
Inflammasome activation after IRI occurs in various organs other than the heart and the kidney, 
including the brain and the liver.45 In these organs, aPC likewise conveys cytoprotection after IRI,15 
suggesting that limiting inflammasome activation by aPC may be relevant not only in the heart and 
kidney (as shown here), but also in other organs. Of note, the 3K3A aPC variant has pronounced 
neuroprotective effects in animal models of cerebral IRI and is undergoing clinical trials in patients 
experiencing stroke (registered at www.clinicaltrials.gov as #NCT02222714).46 Because Nlrp3 
inflammasome inhibition ameliorates experimental cerebral IRI, it is conceivable that aPC restricts 
Nlrp3 inflammasome activation in cerebral IRI, but this remains to be shown. 
Nlrp3 overexpression itself is not sufficient to cause myocardial dysfunction38 (as shown in the current 
study), corroborating that both the priming and activation steps are required for inflammasome 
activation after IRI.38,47 Importantly, by restricting Nlrp3 expression and caspase-1 and IL-1β activation, 
aPC seems to target both inflammasome activation steps. Because the priming step of inflammasome 
activation is largely mediated by NF-κB, and because aPC inhibits NF-κB activity, the proposed function 
of aPC in restricting inflammasome priming is plausible.48,49 Considering the results obtained here using 
aPC and parmodulin-2 or recent studies using small-compound Nlrp3 inhibitors,50 targeting both steps 
of Nlrp3 inflammasome seems to be therapeutically feasible. On the basis of these observations, we 
propose that simultaneously restricting the priming (induction of Nlrp3 expression) and activation 
(formation of the inflammasome complex) steps may be superior to inhibition of IL-1 receptor signaling 
or caspases.5,51,52 
Both canonical (IL-1β, IL-18) and noncanonical (Nlrp3 or caspase-1) inflammasome-dependent effects 
cause tissue damage after IRI.6⇓-8,53 Thus, in myocardial fibroblasts, Nlrp3 induces mitochondrial ROS 
and Smad signaling directly through its NACHT domain.53 Likewise, in renal IRI, Nlrp3 conveys tissue 
damage independent of ASC and cytokine production.54 Whether aPC regulates the canonical Nlrp3 
activation pathway, the noncanonical Nlrp3 activation via caspase-11, or both needs to be further 
evaluated in future studies. 
The current results suggest that inflammasome activation and associated cell death (pyroptosis) are 
mechanistically more relevant than apoptosis in IRI. A role of apoptosis, an immunologically silent cell-
death form, in myocardial IRI has been repeatedly proposed, but these studies have typically used 
terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay, which is not specific for 
apoptosis and additionally detects pyroptosis and other cell-death forms.4,5,17,19 Our in vivo kinetic 
studies demonstrate that inflammasome activation precedes apoptosis (Figure 2). Additionally, Nlrp3 
deficiency is protective in myocardial IRI.6 Inflammasome activation and pyroptosis in tissue-resident 
cells after IRI may generate a proinflammatory micromilieu leading to the recruitment of professional 
immune cells. This may trigger a vicious cycle promoting tissue damage.47,55,56 Targeting the Nlrp3 
inflammasome or caspase-1 may inhibit very early tissue-disruptive events and thus may be superior to 
other approaches limiting inflammation associated with IRI. However, the current study does not 
exclude the occurrence or relevance of apoptosis in IRI. Indeed, the induction of apoptosis at later 
stages after IRI may reflect a protective mechanism, eliminating damaged cells without simultaneously 
inducing an inflammatory response. 
What might be the mechanisms underlying aPC-mediated inflammasome inhibition? Here we show 
that inflammasome inhibition by aPC depends on mTORC1 inhibition. mTORC1 activation and induction 
of HK1 expression and glycolysis constitute a mechanism of Nlrp3, but not of Nlrp1 or Nlrc4, activation 
in macrophages.57 Likewise, we observed inhibition of mTORC1 and HK1 in LPS- and ATP-challenged 
macrophages and cardiac fibroblasts by aPC. In addition, aPC inhibited mTORC1 and HK1 in 
hypoxia/reoxygenation-challenged cardiomyocytes as well as in the heart after myocardial IRI. 
Inhibition of mTORC1 by aPC is congruent with AMPK activation (an inhibitor of mTORC1 signaling) by 
aPC after myocardial infarction.21 mTORC1 activation in IRI has frequently been observed,58,59 
corroborating a mechanistic relevance of mTORC1 inhibition by aPC. We acknowledge that the role of 
mTOR signaling in myocardial IRI is complex and depends on its temporal activation pattern, the cell 
type, the extent of mTOR activity, and the involvement of mTORC1 vs mTORC2.14,41,60 The ability of 
TSC1 deficiency to abolish aPC-mediated mTORC1 inhibition indicates that aPC regulates the mTORC1 
complex.60,61 However, considering the multifaceted interactions of TSC1/TSC2, mTORC1, and mTORC2, 
the precise mechanism needs to be evaluated in future studies. 
We and others have demonstrated that aPC restricts mitochondrial ROS,24,62 a known inducer of Nlrp3 
inflammasome activation.45 Intriguingly, mTORC1 regulates mitochondrial quality and ROS,63 
suggesting that inhibition of mTORC1 and mitochondrial ROS by aPC may be mechanistically linked. 
Because the regulation of mitochondrial ROS and mTORC1 is mutual,64 additional studies are required 
to decipher the exact mechanism through which aPC regulates mTORC1 and mitochondrial ROS. 
Although it provides new insights into the cytoprotective effects of aPC, the current study also raises 
questions. Thus, although parmodulin-2 demonstrated efficacy in the study, it currently remains 
unknown whether mimicking biased signaling via PAR-1 is sufficient to copy the versatile 
cytoprotective effects of aPC. Considering that parmodulin-2 targets Gαq signaling, we suspect that 
aPC–PAR-1–Gαq signaling conveys aPC-mediated inflammasome suppression.32 Furthermore, various 
receptors complement aPC signaling via PAR-1 in cell- and context-specific fashions.26,65,66 The 
coreceptors required for aPC PAR-1–mediated inflammasome suppression remain unknown. 
Deciphering the specific coreceptors and signaling pathways involved may allow further optimization 
of a molecular targeted therapy to inhibit inflammasome activation after IRI. 
Additionally, the long-term outcome after interventions with aPC in the setting of myocardial IRI 
remains to be evaluated. Several groups have shown that inflammasome inhibition improves cardiac 
remodeling and function at later time points.4,5,67 Because aPC ameliorates angiotensin II–triggered 
myocardial remodeling,22 an improved outcome after aPC-mediated inflammasome restriction seems 
conceivable, but this remains to be shown. 
We demonstrate inflammasome suppression by aPC in various cell types relevant in myocardial IRI. 
Whether inflammasome suppression in a particular cell type is more important than in others in the 
context of IRI remains to be shown. Intriguingly, the proposed initiation of a vicious cycle by 
inflammasome activation in tissue-resident cells, which then promotes the recruitment and activation 
of inflammatory cells, implies that it may be sufficient to inhibit inflammasome activation specifically in 
ischemic organs. This may allow tissue protection without compromising the function of innate 
immune cells, which may constitute an advantage in organ transplantation or in patients in an 
intensive care unit setting. 
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